Barclay A. Phillips
Lead Independent DirectorMr. Barclay A. Phillips, also known as Buck, served as Chief Operating Officer and Chief Financial Officer at Ribometrix, Inc. since August 2020 until October 2024. He serves as Managing Member at Domantle Consulting LLC since September 2019. He has experience in growth of biotechnology companies through all stages of development. He has been Lead Independent Director of Immunic, Inc. since 2022 and had been its Independent Director since November 14, 2019. He served as the Chief Financial Officer and Senior Vice President of Corporate Development at G1 Therapeutics, Inc. from November 8, 2017 to May 8, 2019 and as its Secretary until May 2019. At G1 Therapeutics, he was responsible for finance and accounting functions, financing strategy, Wall Street and investor relations, public relations and corporate strategy and corporate development. Mr. Phillips served as the Managing Director of Vector Fund Management, L.P., a venture capital firm focused specifically on healthcare technology, since October 1999 until September 2008. He served as Consultant of Novavax, Inc. since November 10, 2017 until December 31, 2017. He has wide capital markets, financial strategy and business development experience in life sciences and venture capital. Over that period he has served as chief financial officer of three separate NASDAQ-listed biotechnology companies, as a managing director of a biotech focused venture capital fund and as a biotech analyst at a major public mutual fund complex. In addition, Mr. Phillips has served on the board of directors of more than a dozen public or private life sciences companies. Mr. Phillips served as the Chief Financial Officer and Senior Vice President of Novavax, Inc. from June 24, 2013 to November 10, 2017 and its Treasurer from June 24, 2013 to November 10, 2017. He led financial operations at Novavax, Inc. and was part of the executive team responsible for corporate strategy and mergers and acquisitions. While at Novavax, he managed operating expense growth and successfully raised in multiple equity and debt financings. He served as the Chief Financial Officer and Senior Vice President of Micromet, Inc. from September 2008 to March 7, 2012 and served as its Principal Accounting Officer until March 7, 2012. In this role, he successfully raised capital in multiple financings to support high-priority development programs. Prior to joining Vector in November 1999, he served in various roles including Director of Private Placements, Director of Venture Investments and Biotechnology Analyst for INVESCO Funds Group, Inc. from 1991 to 1999. Prior to joining INVESCO Funds Group in 1991, he held positions in sales and trading with Paine Webber Inc. and Shearson Lehman Hutton Inc., from 1985 to 1990. He held positions in trading and sales with Paine Weber Inc. and Shearson Lehman Hutton Inc., respectively. He served at UBS Financial Services Inc. and GE Capital Mortgage Services of California, Inc. He serves as a Director of Cellomics, Inc. He has been a Director of Hologic Surgical Products, Limited Partnership since 2000. He served as a Director of Acorda Therapeutics Inc., from September 2004 to June 22, 2009. He served as a Director of CancerVax Corp. since December 2000 and Micromet, Inc. from December 2000 to September 2008. He served as Corporate Strategy Consultant (Domantle Consulting LLC) at Brii Biosciences since September 2019 until July 2020. He served as Corporate Strategy Consultant (Domantle Consulting LLC) at LifeEDIT since September 2019 until April 2020. He was Financial Consultant Searson Lehman Hutton from 1990 to 1991. Mr. Phillips has a B.A. in Economics from the University of Colorado in Boulder.
Positions
- Company NameImmunic, Inc.Stock CodeIMUXPositionLead Independent DirectorColleagues
- JTJason TardioCOO & President
- MWMichael Weston BonneyChair of the Board
- GWGlenn WhaleyChief Financial Officer
- ELErik LundgrenCEO & Director
- HKHella KohlhofCo-Founder & Chief Scientific Officer
- JBJessica BreuVice President of Investor Relations & Communications
- JNJorg NeermannIndependent Director
- JCJon CongletonIndependent Director
